Size | Price | Stock | Qty |
---|---|---|---|
100mg |
|
||
Other Sizes |
|
ln Vitro |
The growth and Kir3.2 activity of Kir3.2-transformed cells are inhibited in a concentration-dependent manner by proflavine (0.1-10 μM; 24 hours) [1]. The Kir3.2 mutant's current amplitude was progressively decreased to 27.7±4.3% of the control by proflavine (300 μM) [2].
|
---|---|
ln Vivo |
Proflavin (20 mg/kg) concentration in whole blood decreased quickly after intravenous injection and stabilized around half an hour later [3].
|
Cell Assay |
Cell viability assay [2]
Cell Types: Kir3.2* transformant BYT123 Cell Tested Concentrations: 0.1, 1 and 10 μM Incubation Duration: 24 hrs (hours) Experimental Results: Dose-dependent inhibition of Kir3.2* transformant cell growth. Attenuates the growth of Kir3.2*-transformed cells without affecting the growth of control cells. |
Animal Protocol |
Animal/Disease Models: Adult male Sprague Dawley rats (body weight approximately 200 g) [3]
Doses: 20 mg/kg (pharmacokinetic/PK/PK analysis) Route of Administration: intravenous (iv) (iv)injection; 20 mg/kg. Results at 2, 4, 5, 10, 15, 20, 25 and 30 minutes after Route of Administration: Whole blood concentration diminished rapidly in the first 5 minutes after administration, and then diminished slowly. |
References |
[1]. Mansour K.Gatasheh, et al. Proflavine an acridine DNA intercalating agent and strong antimicrobial possessing potential properties of carcinogen. Karbala International Journal of Modern Science. 2017 Dec, 3(4): 272-278.
[2]. Hitoshi Kawada, et al. Isolation of proflavine as a blocker of G protein-gated inward rectifier potassium channels by a cell growth-based screening system. Neuropharmacology. 2016 Oct;109:18-28. [3]. Jiaxin Chen, et al. Determination of proflavine in rat whole blood without sample pretreatment by laser desorption postionization mass spectrometry. Anal Bioanal Chem. 2017 Apr;409(11):2813-2819. |
Molecular Formula |
C26H24N6O4S
|
---|---|
Molecular Weight |
516.57
|
CAS # |
1811-28-5
|
Related CAS # |
Proflavine;92-62-6;Proflavine dihydrochloride;531-73-7
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
NC1=CC2=NC3=CC(N)=CC=C3C=C2C=C1.[0.5H2SO4]
|
Synonyms |
Proflavine hemisulfate dihydrate 3,6 Diamino Acridine 3,6 Diaminoacridine 3,6-diamino acridine Proflavine hemisulfate EINECS 217-320-3 3,6-Acridinediamine, sulfate (2
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
H2O : ≥ 5 mg/mL (~19.36 mM)
|
---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.9358 mL | 9.6792 mL | 19.3585 mL | |
5 mM | 0.3872 mL | 1.9358 mL | 3.8717 mL | |
10 mM | 0.1936 mL | 0.9679 mL | 1.9358 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.